Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donanemab in Indian Participants With Early Symptomatic Alzheimer's Disease
NCT07838155Phase 4Not yet recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2026
- Primary completion
- Sep 2030
- Countries
- 1
01
Overview
A Phase 4 trial of donanemab in Alzheimer's disease (AD), sponsored by Eli Lilly and Company. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
donanemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07838155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07838155.